Millipore Sigma Vibrant Logo

505308 CDDO-Me - CAS 218600-53-4 - Calbiochem

505308
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₃₂H₄₃NO₄ 218600-53-4

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.05308.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable, bioavailable synthetic oleanane triterpenoid compound with anti-inflammatory, anti-tumor and cytoprotective properties. Shown to significantly reduce the expression of several inflammatory mediators, including IL-6, IL-10, IL-12, TNFα, Mip1α and others. Reverses high fat diet-induced type 2 diabetes in C57BL/6 mice (3 mg/kg) and improves glucose homeostasis and insulin sensitivity. Down-regulates lipogenic gene expression in hepatocytes. Exhibits anti-proliferative activity in osteosarcoma cells (IC50 = 800, 150, 330, and 170 nM in HOB-c, KHOS, KHOSR2, and U2OS cells, respectively). Enhances the effectiveness of chemotherapeutic agents by inducing intrinsic mitochondrial-dependent apoptotic pathway. Reported to interact with multi cellular targets, namely, Nrf2-Keap1, IKK, JAK-STAT, PPARγ, ErbB2, PTEN, mTOR and Arp3 and covalently modify active site Cys residue via Michael addition.
      Catalogue Number505308
      Brand Family Calbiochem®
      SynonymsNrf Activator V, NSC 713200, Bardoxolone methyl, BARD, Methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate
      References
      ReferencesLiby, K.T. and Sporn, M.B., 2012. Pharmacol. Rev. 64, 972.
      Saha, P.K. et al. 2010. J. Biol. Chem. 285, 40581.
      Ryu, K., et al. 2010. BMC Cancer 10, 187.
      Liby, K.T., et al. 2007. Nat. Rev. Cancer 7, 357.
      Shishodia S., et al. 2006. Clin. Cancer Res. 12, 1828.
      Zou, W., et al. 2004. Cancer Res. 64, 7570.
      Kim, Y., et al. 2002. J. Biol. Chem. 277, 22320.
      Konopleva, M., et al. 2002. Blood 99, 326.
      Wang, Y., et al. 2000. Mol Endocrinol. 14, 1550.
      Product Information
      CAS number218600-53-4
      FormWhite solid
      Hill FormulaC₃₂H₄₃NO₄
      Chemical formulaC₃₂H₄₃NO₄
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      CDDO-Me - CAS 218600-53-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Liby, K.T. and Sporn, M.B., 2012. Pharmacol. Rev. 64, 972.
      Saha, P.K. et al. 2010. J. Biol. Chem. 285, 40581.
      Ryu, K., et al. 2010. BMC Cancer 10, 187.
      Liby, K.T., et al. 2007. Nat. Rev. Cancer 7, 357.
      Shishodia S., et al. 2006. Clin. Cancer Res. 12, 1828.
      Zou, W., et al. 2004. Cancer Res. 64, 7570.
      Kim, Y., et al. 2002. J. Biol. Chem. 277, 22320.
      Konopleva, M., et al. 2002. Blood 99, 326.
      Wang, Y., et al. 2000. Mol Endocrinol. 14, 1550.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision26-July-2013 JSW
      SynonymsNrf Activator V, NSC 713200, Bardoxolone methyl, BARD, Methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate
      DescriptionA cell-permeable, bioavailable synthetic oleanane triterpenoid compound with anti-inflammatory, anti-tumor and cytoprotective properties. Shown to significantly reduce the expression of several inflammatory mediators, including IL-6, IL-10, IL-12, TNFα, Mip1α and others. Reverses high fat diet-induced type 2 diabetes in C57BL/6 mice (3 mg/kg) and improves glucose homeostasis and insulin sensitivity. Down-regulates lipogenic gene expression in hepatocytes. Exhibits anti-proliferative activity in osteosarcoma cells (IC50 = 800, 150, 330, and 170 nM in HOB-c, KHOS, KHOSR2, and U2OS cells, respectively). Enhances the effectiveness of chemotherapeutic agents by inducing intrinsic mitochondrial-dependent apoptotic pathway. Reported to interact with multi cellular targets, namely, Nrf2-Keap1, IKK, JAK-STAT, PPARγ, ErbB2, PTEN, mTOR and Arp3 and covalently modify active site Cys residue via Michael addition.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number218600-53-4
      Chemical formulaC₃₂H₄₃NO₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml). Use only fresh DMSO for reconstitution.
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesLiby, K.T. and Sporn, M.B., 2012. Pharmacol. Rev. 64, 972.
      Saha, P.K. et al. 2010. J. Biol. Chem. 285, 40581.
      Ryu, K., et al. 2010. BMC Cancer 10, 187.
      Liby, K.T., et al. 2007. Nat. Rev. Cancer 7, 357.
      Shishodia S., et al. 2006. Clin. Cancer Res. 12, 1828.
      Zou, W., et al. 2004. Cancer Res. 64, 7570.
      Kim, Y., et al. 2002. J. Biol. Chem. 277, 22320.
      Konopleva, M., et al. 2002. Blood 99, 326.
      Wang, Y., et al. 2000. Mol Endocrinol. 14, 1550.